Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Gene Ther
2020 Feb 01;271-2:51-61. doi: 10.1038/s41434-019-0096-1.
Show Gene links
Show Anatomy links
Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo.
Xande JG
,
Dias AP
,
Tamura RE
,
Cruz MC
,
Brito B
,
Ferreira RA
,
Strauss BE
,
Costanzi-Strauss E
.
???displayArticle.abstract???
Cancer therapies that target a single protein or pathway may be limited by their specificity, thus missing key players that control cellular proliferation and contributing to the failure of the treatment. We propose that approaches to cancer therapy that hit multiple targets would limit the chances of escape. To this end, we have developed a bicistronic adenoviral vector encoding both the CDKN2A and p53 tumor suppressor genes. The bicistronic vector, AdCDKN2A-I-p53, supports the translation of both gene products from a single transcript, assuring that all transduced cells will express both proteins. We show that combined, but not single, gene transfer results in markedly reduced proliferation and increased cell death correlated with reduced levels of phosphorylated pRB, induction of CDKN1A and caspase 3 activity, yet avoiding the induction of senescence. Using isogenic cell lines, we show that these effects were not impeded by the presence of mutant p53. In a mouse model of in situ gene therapy, a single intratumoral treatment with the bicistronic vector conferred markedly inhibited tumor progression while the treatment with either CDKN2A or p53 alone only partially controlled tumor growth. Histologic analysis revealed widespread transduction, yet reduced proliferation and increased cell death was associated only with the simultaneous transfer of CDKN2A and p53. We propose that restoration of two of the most frequently altered genes in human cancer, mediated by AdCDKN2A-I-p53, is beneficial since multiple targets are reached, thus increasing the efficacy of the treatment.
Bajgelman,
Exploration of critical parameters for transient retrovirus production.
2003, Pubmed
Bajgelman,
Exploration of critical parameters for transient retrovirus production.
2003,
Pubmed
Beckerman,
Transcriptional regulation by p53.
2010,
Pubmed
Carr,
Defining actionable mutations for oncology therapeutic development.
2016,
Pubmed
Chen,
The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.
2016,
Pubmed
Chen,
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.
2014,
Pubmed
Colombo,
Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results.
2005,
Pubmed
Costanzi-Strauss,
Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines.
1998,
Pubmed
Debacq-Chainiaux,
Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo.
2009,
Pubmed
Deben,
TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.
2016,
Pubmed
Freed-Pastor,
Mutant p53: one name, many proteins.
2012,
Pubmed
Freytag,
Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
2003,
Pubmed
Friedman,
Precision medicine for cancer with next-generation functional diagnostics.
2015,
Pubmed
Futreal,
A census of human cancer genes.
2004,
Pubmed
Ghaneh,
Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.
2001,
Pubmed
Ghattas,
The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos.
1991,
Pubmed
Helsten,
Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics.
2016,
Pubmed
Jamal-Hanjani,
Tracking the Evolution of Non-Small-Cell Lung Cancer.
2017,
Pubmed
Kaye,
RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer.
2002,
Pubmed
Khoo,
Drugging the p53 pathway: understanding the route to clinical efficacy.
2014,
Pubmed
Kim,
High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice.
2011,
Pubmed
Lane,
p53-based cancer therapy.
2010,
Pubmed
Lu,
Tied up in loops: positive and negative autoregulation of p53.
2010,
Pubmed
Meek,
Posttranslational modification of p53: cooperative integrators of function.
2009,
Pubmed
Melero,
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
2015,
Pubmed
Miciak,
Long story short: p53 mediates innate immunity.
2016,
Pubmed
Muller,
Mutant p53 in cancer: new functions and therapeutic opportunities.
2014,
Pubmed
Naviaux,
The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.
1996,
Pubmed
Nguyen,
Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer.
1996,
Pubmed
Nyberg-Hoffman,
Sensitivity and reproducibility in adenoviral infectious titer determination.
1997,
Pubmed
Okada,
Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response.
2000,
Pubmed
Oren,
Mutant p53 gain-of-function in cancer.
2010,
Pubmed
Robles,
Clinical outcomes and correlates of TP53 mutations and cancer.
2010,
Pubmed
Roth,
Adenovirus p53 gene therapy.
2006,
Pubmed
Rozen,
Primer3 on the WWW for general users and for biologist programmers.
2000,
Pubmed
Sandig,
Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death.
1997,
Pubmed
Sherr,
Targeting CDK4 and CDK6: From Discovery to Therapy.
2016,
Pubmed
Strauss,
Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats.
2002,
Pubmed
Strauss,
The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins.
1995,
Pubmed
Szymczak-Workman,
Design and construction of 2A peptide-linked multicistronic vectors.
2012,
Pubmed
Tomayko,
Determination of subcutaneous tumor size in athymic (nude) mice.
1989,
Pubmed
VanderVeen,
Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
2016,
Pubmed
Vanneman,
Combining immunotherapy and targeted therapies in cancer treatment.
2012,
Pubmed
Wang,
p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.
2015,
Pubmed
